Drugs / Leritrelvir
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06160622 | Sep → Dec 2023 | impaired renal function disease | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06161259 | Sep → Oct 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06031454 | Sep → Nov 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06169085 | Aug → Sep 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leritrelvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06161259 ↗ |
| Known as | RAY1216 | “A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Severe Kidney Impairment on the Pharmacokinetics, Safety and Tolerability...” NCT06160622 ↗ |
| Action | Inhibit | “It also inhibits CYP3A, CYP2C19, and OATP1B3.” PMID 42062754 ↗ May 2026 |
| Route | Oral | “Oral” NCT06160622 ↗ |